Ortmann, Brian M.
Burrows, Natalie http://orcid.org/0000-0001-6591-5971
Lobb, Ian T.
Arnaiz, Esther http://orcid.org/0000-0001-7838-4575
Wit, Niek
Bailey, Peter S. J. http://orcid.org/0000-0001-7707-3521
Jordon, Louise H.
Lombardi, Olivia
PeƱalver, Ana
McCaffrey, James http://orcid.org/0000-0002-2964-9036
Seear, Rachel
Mole, David R.
Ratcliffe, Peter J.
Maxwell, Patrick H.
Nathan, James A. http://orcid.org/0000-0002-0248-1632
Funding for this research was provided by:
Wellcome Trust (215477/Z/19/Z)
Lister Institute of Preventive Medicine
Wellcome Trust
Article History
Received: 29 September 2020
Accepted: 14 May 2021
First Online: 21 June 2021
Competing interests
: P.J.R. is a scientific cofounder of ReOx Ltd., a company that is developing inhibitors of the HIF hydroxylase enzymes. P.H.M. is a scientific cofounder and equity holder of ReOx and has received speaker honoraria from Fibrogen, both of which aim to develop PHD inhibitors as therapies. The other authors declare no competing interests.